ATE538096T1 - Pyridinon-derivate zur behandlung von arteriosklerose - Google Patents

Pyridinon-derivate zur behandlung von arteriosklerose

Info

Publication number
ATE538096T1
ATE538096T1 AT01978400T AT01978400T ATE538096T1 AT E538096 T1 ATE538096 T1 AT E538096T1 AT 01978400 T AT01978400 T AT 01978400T AT 01978400 T AT01978400 T AT 01978400T AT E538096 T1 ATE538096 T1 AT E538096T1
Authority
AT
Austria
Prior art keywords
arteriosclerosis
treatment
pyridinone derivatives
pyridinone
derivatives
Prior art date
Application number
AT01978400T
Other languages
English (en)
Inventor
Deirdre HICKEY
Robert IFE
Colin LEACH
John Liddle
Ivan PINTO
Stephen Smith
Steven STANWAY
Original Assignee
Smithkline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Ltd filed Critical Smithkline Beecham Ltd
Application granted granted Critical
Publication of ATE538096T1 publication Critical patent/ATE538096T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01978400T 2000-10-10 2001-10-05 Pyridinon-derivate zur behandlung von arteriosklerose ATE538096T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024808.8A GB0024808D0 (en) 2000-10-10 2000-10-10 Novel compounds
PCT/EP2001/011610 WO2002030904A1 (en) 2000-10-10 2001-10-05 Pyridinone derivatives for treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
ATE538096T1 true ATE538096T1 (de) 2012-01-15

Family

ID=9901006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01978400T ATE538096T1 (de) 2000-10-10 2001-10-05 Pyridinon-derivate zur behandlung von arteriosklerose

Country Status (28)

Country Link
US (2) US20040063753A1 (de)
EP (2) EP1326841B1 (de)
JP (1) JP4212354B2 (de)
KR (1) KR100824134B1 (de)
CN (2) CN1951917B (de)
AR (1) AR035349A1 (de)
AT (1) ATE538096T1 (de)
AU (2) AU2002210524B2 (de)
BR (1) BRPI0114576B1 (de)
CA (1) CA2425268C (de)
CY (2) CY1112442T1 (de)
CZ (1) CZ304558B6 (de)
DK (2) DK2258688T3 (de)
ES (2) ES2378059T3 (de)
GB (1) GB0024808D0 (de)
GC (1) GC0000307A (de)
HU (1) HU230767B1 (de)
IL (2) IL155278A0 (de)
MX (1) MXPA03003176A (de)
MY (1) MY135766A (de)
NO (1) NO325107B1 (de)
NZ (1) NZ525225A (de)
PL (1) PL207560B1 (de)
PT (2) PT2258688E (de)
SI (2) SI1326841T1 (de)
TW (1) TWI293293B (de)
WO (1) WO2002030904A1 (de)
ZA (1) ZA200302785B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60139429D1 (de) * 2000-02-16 2009-09-10 Smithkline Beecham Plc Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127140D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US7741020B2 (en) 2004-04-16 2010-06-22 Glaxo Group Limited Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US7705005B2 (en) * 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US9029383B2 (en) * 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
BRPI0721697A2 (pt) 2007-05-11 2014-08-05 Univ Jefferson " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
US9512104B2 (en) * 2009-07-28 2016-12-06 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A2
US8575348B2 (en) 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
EP2490693A4 (de) * 2009-10-19 2013-02-27 Merck Sharp & Dohme Pyrazolo-[3,4-b-]pyridin-4-on-kinasehemmer
AU2011268127B2 (en) 2010-06-18 2016-01-14 Whitehead Institute For Biomedical Research PLA2G16 as a target for antiviral compounds
US8637536B2 (en) * 2010-12-06 2014-01-28 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
WO2012075917A1 (en) * 2010-12-06 2012-06-14 Glaxo Group Limited Compounds
EP2651403B1 (de) 2010-12-17 2020-12-02 Glaxo Group Limited Verwendung von lp-pla2-inhibitoren zur behandlung und vorbeugung von augenerkrankungen
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
US9273054B2 (en) 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors
EP2739627A4 (de) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-dihydroimidazo-[1,2-c-] pyrimidin-5 (1h)-on-verbindungen als lp-pla²- inhibitoren
US9227953B2 (en) 2011-09-01 2016-01-05 Glaxo Group Limited Crystal form
CA2899124A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
JP2016505053A (ja) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物
WO2014114694A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
EP2764866A1 (de) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Hemmer der nedd8-aktivierenden Enzyme
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
CN107709314A (zh) 2015-06-11 2018-02-16 巴斯利尔药物国际股份公司 外排泵抑制剂及其治疗性用途
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
CN114805389B (zh) 2019-11-09 2023-08-29 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN112510260B (zh) * 2020-11-27 2022-11-04 珠海市赛纬电子材料股份有限公司 电解液添加剂、非水电解液和锂离子电池
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
JP2026516205A (ja) 2023-04-18 2026-05-20 サイニューロ セラピューティクス インコーポレイテッド Ｌｐ－ｐｌａ２阻害剤と第２の薬剤の併用治療
CN118221687B (zh) 2023-07-17 2024-12-31 上海枢境生物科技有限公司 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5769527A (en) 1986-07-17 1998-06-23 Vari-Lite, Inc. Computer controlled lighting system with distributed control resources
US5585246A (en) 1993-02-17 1996-12-17 Biometric Imaging, Inc. Method for preparing a sample in a scan capillary for immunofluorescent interrogation
WO1995000649A1 (en) 1993-06-25 1995-01-05 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
EP1096016B1 (de) 1993-10-06 2006-01-11 Icos Corporation Acethylhydrolase des Plättchen aktivierenden Faktors
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
WO1996019451A1 (en) 1994-12-22 1996-06-27 Smithkline Beecham Plc Substituted azetidin-2-ones for treatment of atherosclerosis
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
HUP9901153A3 (en) 1995-07-01 1999-11-29 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them
FR2743912B1 (fr) 1996-01-24 1998-04-10 Matra Communication Circuit de resolution d'equation-cle et decodeur reed-solomon incorporant un tel circuit
US5684794A (en) 1996-01-25 1997-11-04 Hazeltine Corporation Validation of subscriber signals in a cellular radio network
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
CA2274093C (en) * 1996-12-05 2006-11-07 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
WO1999024420A1 (en) * 1997-11-06 1999-05-20 Smithkline Beecham Plc Pyrimidinone compounds and pharmaceutical compositions containing them
DE69911980T2 (de) 1998-08-21 2004-09-09 Smithkline Beecham P.L.C., Brentford Pyrimidinonderivate zur behandlung von atheroscleros
DE60042286D1 (de) 1999-05-01 2009-07-09 Smithkline Beecham Plc Pyrimidinon Verbindungen
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
PT2258688E (pt) 2013-02-04
PT1326841E (pt) 2012-03-08
HUP0302480A2 (hu) 2003-12-29
NZ525225A (en) 2004-10-29
BR0114576A (pt) 2004-07-27
NO20031626D0 (no) 2003-04-09
US20040063753A1 (en) 2004-04-01
BRPI0114576B1 (pt) 2017-05-30
CN1951917A (zh) 2007-04-25
ZA200302785B (en) 2004-07-09
MXPA03003176A (es) 2003-07-14
JP4212354B2 (ja) 2009-01-21
HK1144941A1 (en) 2011-03-18
US7235566B2 (en) 2007-06-26
CN1280275C (zh) 2006-10-18
EP1326841B1 (de) 2011-12-21
PL366334A1 (en) 2005-01-24
CN1479724A (zh) 2004-03-03
IL155278A (en) 2015-05-31
IL155278A0 (en) 2003-11-23
CN1951917B (zh) 2012-07-18
SI2258688T1 (sl) 2013-03-29
ES2399325T3 (es) 2013-03-27
AU1052402A (en) 2002-04-22
KR20030036916A (ko) 2003-05-09
WO2002030904A1 (en) 2002-04-18
PL207560B1 (pl) 2011-01-31
HK1058036A1 (en) 2004-04-30
CZ304558B6 (cs) 2014-07-09
CA2425268A1 (en) 2002-04-18
EP2258688B1 (de) 2012-11-21
DK2258688T3 (da) 2013-02-04
HU230767B1 (hu) 2018-03-28
NO20031626L (no) 2003-06-04
US20050014793A1 (en) 2005-01-20
AU2002210524B2 (en) 2004-06-03
GB0024808D0 (en) 2000-11-22
CY1113648T1 (el) 2016-06-22
CZ20031009A3 (cs) 2003-11-12
JP2004512283A (ja) 2004-04-22
GC0000307A (en) 2006-11-01
EP1326841A1 (de) 2003-07-16
KR100824134B1 (ko) 2008-04-21
HUP0302480A3 (en) 2010-03-29
DK1326841T3 (da) 2012-02-27
TWI293293B (en) 2008-02-11
NO325107B1 (no) 2008-02-04
CA2425268C (en) 2011-09-13
CY1112442T1 (el) 2015-12-09
EP2258688A1 (de) 2010-12-08
ES2378059T3 (es) 2012-04-04
MY135766A (en) 2008-06-30
SI1326841T1 (sl) 2012-04-30
AR035349A1 (es) 2004-05-12

Similar Documents

Publication Publication Date Title
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
ATE265860T1 (de) Impstoff zur behandlung von atherosclerosis
DE60138129D1 (de) Apparat zur behandlung von zähnen
DE60011570D1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE60019195D1 (de) Behandlung durch Ablation von Knochenmetastasen
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
NO20031626L (no) Pyridonderivater for behandling av atherosklerose
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
ATE279386T1 (de) Retinoide zur behandlung von emphysem
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
EP1117431A4 (de) Behandlung von acidose
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
DE60103685D1 (de) Behandlung von Poriomania
DE60026821D1 (de) Behandlung von bohrspülung